Treatment Of Depression – Tenil Thu, 17 Nov 2022 23:34:07 +0000 en-US hourly 1 Treatment Of Depression – Tenil 32 32 The Trilingual Therapy Dog – UND Today Thu, 17 Nov 2022 23:34:07 +0000

Life on the UND flight line is made a little easier by Brita, a therapy dog ​​wearing aviator goggles and a bomber hat

Therapy dog ​​Brita visits UND student Abbie Ritchie (left) and Cassandra Bills, a certified flight instructor, at the UND Airport Flight Operations Center. All photos by Arjun Jagada/Odegard School of Aerospace Sciences.

By Mackinney Supola

Nothing is more relaxing after a stressful and exhausting flying lesson than sitting with a giant schnauzer on an expedition. Especially when that four-legged friend is Brita the therapy dog, a dog best known in UND air operations for her aviator goggles and old-fashioned bomber hat.

Pet therapy is a type of therapy that uses an animal to improve an individual’s social, emotional, or cognitive state. Several research papers have shown the benefits of pet therapy in areas such as patient satisfaction, energy levels, self-esteem, and mood, as well as in decreasing depression.

Laurel Johnson and her 10-year-old dog, Brita, do a lot of volunteer work around the University of North Dakota as well as in the community of Grand Forks. And every third Wednesday of the month, the duo meet at flight operations to comfort flight students, flight instructors and anyone else who might cross their path.

Laurel Johnson and her therapy dog, Brita.

Johnson was introduced to pet therapy as a child, when she took her dog with her when she visited her elderly neighbor. She has been more formally involved in pet therapy since 2007. She first started with her dog Molly, a white poodle mix, who has since passed away.

Brita was originally purchased by a dog trainer in Minnesota, where she was intended to be a breeding dog for future service dogs. However, after Brita was discovered to have a disqualifying genetic condition, she was no longer eligible to be a breeding dog in the service dog industry.

But while service dogs are trained to work with people with disabilities, therapy dogs serve a different helping role. So around the time Brita was found to be ineligible to be a service dog, Johnson – who was friends with the dog trainer – offered to take Brita on therapy visits.

Within a year, Johnson became the owner of Brita and their career as a therapy dog ​​team began.

English, German and American Sign Language

Brita has been trained in German commands and responds to both English and German. Additionally, Brita knows over 40 American Sign Language words, as Johnson is a retired interpreter for the deaf. In 2012, when her dog Molly became deaf, Johnson continued to communicate with her through sign language, a practice she continued with Brita when she took possession of it.

When asked to share one of the couple’s most defining moments, Johnson recalled a visit she had to Altru Hospital with a patient in poor condition whose family was out of the way. town. When they arrived at the hospital, the nurses were “out of their minds and knelt in stress when they saw Brita and hugged her,” Johnson said. (As Johnson noted, therapy dogs in health care settings can very often help relieve stress not only for patients but also for staff.)

Brita then visited the patient for a little while, then the couple left the room to go visit other patients, with the promise to come back to say goodbye before leaving.

Upon their return, they learned that the patient had died shortly after their visit. “It took my breath away,” Johnson said. “I was so grateful to bring any comfort to this human being at the time of his death and to bring the last smile to this person’s face.”

Johnson also described time spent with Brita in intensive care, comforting the families of intensive care patients.

Brita the therapy dog.

Brita’s first connection to UND came eight years ago, when she and Johnson volunteered at an anti-stress festival at Memorial Union. Students would line up for over an hour to see Brita or one of the other therapy dogs visiting that day, Johnson recalled.

Through these visits, Johnson got to know students and staff from other departments and expanded his visits to more areas.

Upon learning in the fall of 2021 of the recent death of an aviation student, Johnson called the aviation department and offered to bring Brita to the students’ presence. She hoped she and Brita could provide some level of comfort, she said. Since that time, she and Brita have brought smiles to flight students through their regular visits to flight operations.

Meaning and purpose

“She walked into Ryan Hall while I was working,” one UND aviation student said when asked about Brita, “and I got to see her for a brief time. I love animals, and dogs help Really improving every day!It was a bright time of day that was needed during a busy week.

The work Brita and Johnson do is entirely voluntary, although that fact has never deterred Johnson from finding the motivation to get out and help others. “It’s something that gives me meaning and purpose, and I can do that with my best friend,” she said.

Looking ahead, Johnson says he’s excited to attend and speak at the Aviation Mental Health Symposium, which is scheduled for this week. Brita and Johnson will be hosting the event at the door, and Johnson is to give a presentation on pet therapy.


Mackinney Supola

About the Author:

A certified flight instructor, Mackinney Supola is pursuing a bachelor’s degree in commercial aviation and communications at UND. She is currently a marketing intern in the dean’s office of the university’s Odegard School of Aerospace Sciences.

Extremely stressful events worsen symptoms of long COVID Wed, 09 Nov 2022 18:53:58 +0000

JThe death of a loved one, financial or food insecurity, or a newly developed disability were among the strongest predictors of whether a patient hospitalized with COVID-19 would experience COVID-long symptoms a year later, a new study finds. .

Led by researchers at NYU Grossman School of Medicine, the study found that adult patients with such “major life stressors” – present in more than 50% of those followed – were at least twice as likely to fight depression, brain fog, fatigue, sleep problems and other long-term symptoms of COVID-19.

Published online this week in the Journal of Neurological Sciencesthe analysis also confirmed the contribution of traditional factors to greater long-term COVID risk, as shown in previous studies – older age, level of disability to begin with, and more severe initial case of COVID-19 .

“Our study is unique in that it explores the impact of life stressors, as well as demographic trends and neurological events, as predictors of long-term cognitive and functional impairments that affect the quality of lives of a large population,” says the study’s lead author, Jennifer A. Frontera, MD, a professor in the Department of Neurology at NYU Langone Health. “Therapies that lessen the trauma of the most stressful life events must be a central part of the treatment of long COVIDs, with more research needed to validate the best approaches.”

The research used standard telephone survey tools in the field – the Modified Rankin Scale (mRS), Barthel Index, Montreal Cognitive Assessment (t-MoCA) and National Institutes of Health (NIH )/Patient-Reported Outcomes Measurement Information System (PROMIS) Neurological Quality of Life (NeuroQoL) batteries – to measure level of daily functioning, clear thinking (cognition), anxiety, depression, fatigue and quality of sleep. The team attempted to follow each of the 790 patients 6 months and one year after hospitalization for COVID-19 at NYU Langone Health between March 10, 2020 and May 20, 2020.

Of these surviving patients, 451 (57%) completed 6-month and/or 12-month follow-up and, of these, 17% died between discharge and 12-month follow-up and 51% reported important factors stress at the time of consultation. 12 months.

In analyzes that compared factors against each other for their contribution to worst outcomes, life stressors including financial insecurity, food insecurity, death of a close contact, and new disability, were the strongest independent predictors of prolonged COVID-19 symptoms. These same stressors also predicted worse functional status, depression, fatigue, sleep scores, and reduced ability to participate in activities of daily living such as feeding, dressing, and bathing.

Gender also played a role, as previous studies have shown that women are generally more susceptible to, for example, autoimmune diseases which could impact the results. Additionally, undiagnosed mood disorders may have been unmasked by pandemic-related stressors.

The long neurological COVID can include more than one condition

A second study led by Dr. Frontera and colleagues, and published online September 29, 2022, in PLOS ONEfound that patients diagnosed with long-lasting COVID neurological issues can be divided into three symptom clusters.

Because there is no current biological definition of long COVID, many studies lump together disparate symptoms into what is currently a general diagnosis, and without assessment of clinical relevance, Dr. Frontera says. The resulting vagueness has made it “difficult to assess treatment strategies”.

For the PLOS A study, the research team collected data on symptoms, treatments received, and outcomes for 12 months after hospitalization with COVID-19, with treatment success again measured by standard measures (modified Rankin Scale , Barthel Index, NIH NeuroQoL). The three newly identified disease groups were:

  • Group 1: few symptoms (most often headaches) having received few therapeutic interventions
  • Group 2: many symptoms including anxiety and depression who received multiple treatments, including antidepressants to psychological therapy
  • Group 3: mainly pulmonary symptoms such as shortness of breath; many patients also complained of headaches and cognitive symptoms, and mostly received physical therapy

The most severely affected patients (symptom group 2) had higher rates of disability and worse measures of anxiety, depression, fatigue and sleep disturbance. All patients whose treatment included psychiatric therapies reported improvement in symptoms, compared with 97% who received primarily physical or occupational therapy and 83% who received little intervention.

The Brookings Institution estimated in August 2022 that approximately 16 million Americans of working age (ages 18–65) have Long COVID, of which 2–4 million are out of work due to Long COVID.

With Dr Frontera, authors of the Journal of Neurological Sciences NYU Langone Health Department of Neurology study were Sakinah B. Sabadia, Ariane Lewis, Aaron S. Lord, Kara R. Melmed, Sujata P. Thawani, Laura J. Balcer, Thomas M. Wisniewski, and Steven L. Galetta. The authors were also Dixon Yang of the Department of Neurology at NewYork-Presbyterian, Columbia Medical Center; Adam de Havenon of the Department of Neurology at Yale University School of Medicine; and Shadi Yaghi from the Department of Neurology at Brown University School of Medicine.

Media inquiries

Greg Williams
Phone: 212-404-3500

How to stay healthy on vacation – Newsroom Mon, 07 Nov 2022 12:02:56 +0000

November 7, 2022

Exercising can fight stress and balance holiday excess

Posted in: Education, Faculty Voices, Home Page News, Human Services

All those articles and tips you might see this holiday season about burning Thanksgiving dinner?

Ignore them – regular binge eating over a period of weeks or months can indeed affect weight and body fat, but Evan Matthews, associate professor of exercise science and physical education, says overeating in course of a single meal will not have a significant impact on your body.

Instead, make a plan to stay active all winter long — not just when you feel “guilty” about having a few too many glasses of eggnog. Here, Matthews shares tips on maintaining consistent physical activity during the colder months to balance out big dinners, toast, and holiday treats.

How to exercise safely in winter

  • Safety first! When exercising outdoors, be sure to dress in layers. Remove one layer at a time when you’re hot – the goal is to be warm, but to avoid excessive sweating, which can increase the risk of hypothermia.
  • Avoid early morning or late evening workouts in cold weather. This will allow you to exercise when the temperature is near the highest it will be during the day. Also try to avoid bad weather like rain, snow and strong wind.
  • Follow security protocols. Consider local and current COVID-19 guidelines before deciding to exercise indoors with other people.

Simple ways to exercise

  • Train at home. Investing in home exercise equipment will reduce the barriers to exercise associated with the “need to go to the gym” mentality.
  • No equipment? No problem. Cardiorespiratory and resistance exercises can include walking, running, and bodyweight calisthenics.

Customize your training plan

  • Find an exercise buddy. Build in-person or virtual social relationships around your exercise habits to promote exercise adherence.
  • Plan it into your existing routine instead of reorganizing your whole life around exercise. Adults should accumulate 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity cardiorespiratory exercise per week. “Cardiorespiratory exercise can be broken up throughout the day into 10-minute chunks rather than all at once,” says Matthews. “It makes walking and other forms of exercise easier during short breaks throughout the day.”

Focus on the benefits of exercise to stay motivated

  • Good for the body… “Exercise is well known to improve physical health, including reducing blood pressure, cholesterol, body fat and insulin resistance. All of this decreases the likelihood or severity of many cardiometabolic diseases,” says Matthews.
  • … and the spirit. Studies strongly suggest that exercise can “reduce anxiety and depression in everyone, no matter how severe your symptoms are,” he says. “In fact, cardiorespiratory exercise has been shown to be as effective as psychotherapy or pharmacotherapy in treating depression. Exercise can also be used in conjunction with other mental health treatments to improve anxiety and depression, including conditions like seasonal affective disorder.

Make exercise a year-round activity

Evan Matthews
Evan Matthews

Matthews’ tips for creating an active cardiorespiratory and resistance exercise routine can be maintained year-round. “The positive impacts on physical and mental health are greater with long-term exercise adoption,” he says. “And some of the most basic forms of exercise can not only help you on vacation, but help you throughout the year.”

To interview Evan Matthews, please contact the Media Relations team.

Psychedelic drug ‘magic mushroom’ can ease some depression Fri, 04 Nov 2022 23:57:00 +0000

(AP) – The psychedelic chemical in “magic mushrooms” may ease depression in some hard-to-treat patients, a preliminary study has found.

The effects were modest and diminished over time, but they occurred with a single experimental dose in people who had previously obtained little relief from standard antidepressants.

The study is part of a resurgence in research into the potential medical uses of hallucinogenic drugs, and the findings echo findings from smaller studies of the mushroom compound psilocybin. The researchers said larger, longer studies are needed to determine the effectiveness and safety of using psilocybin for depression. Their findings were published Wednesday in the New England Journal of Medicine.

“The results are both intriguing and sobering,” said Bertha Madras, professor of psychobiology and researcher at Harvard Medical School.

Commenting in a journal editorial, Madras said the study is the most rigorous study to date evaluating psilocybin for the treatment of depression. She did not participate in the research.

The researchers tested the chemical on 233 adults in the United States, Europe and Canada. Each swallowed capsule contains one of three doses of psilocybin for a 6-8 hour session. Two mental health specialists guided them through hallucinatory experiences.

The results for the highest and middle doses were compared to those of the very low dose control group. There was no comparison with an inactive dummy drug or with conventional antidepressants, and there were other limitations.

Symptoms of depression decreased in all three groups, with the greatest initial improvement in the group receiving the highest dose. After three weeks, 37% of high-dose recipients had significantly improved. But these effects weren’t as good as those seen in studies of standard antidepressants, and the results waned over the following weeks.

At three months, 20% of the high-dose group still saw substantial improvement.

Compass Pathways, a London-based company that develops psilocybin for commercial use, funded and helped conduct the study. He recently announced that he was launching a larger, more rigorous study.

Side effects, including headaches and nausea, were common in all three study groups. Serious side effects were rare, but they included suicidal thoughts and self-harm – mostly in participants with a history of suicidal thoughts.

Dr. David Hellerstein, co-author and research psychiatrist at Columbia University, said these side effects are not surprising given the intensity of the psychedelic experience from the drug. But he said they stress the importance of using psilocybin in a medical setting.

“It’s not a home run, but it’s very encouraging,” Hellerstein said, noting that improvement was seen after just one dose.

However, he said it was likely that additional doses would be needed to achieve lasting results. This could make use expensive, given the need for several hours of treatment under medical supervision.

Over 180 studies on psilocybin and other psychedelics for use in depression, PTSD, and other mental disorders are listed on the National Library of Medicine website.

The US government still classifies the chemical as a controlled substance, with no accepted medical use. Several cities have already decriminalized magic mushrooms, and Oregon is the first state to approve medical use.

Philip Corlett, associate professor of psychiatry at Yale University, said many significant challenges remain, including determining whether psilocybin has any real effect in reducing depression.

One theory is that it stimulates parts of the brain that control levels of the mood-influencing chemical serotonin. It may also reconnect brain circuitry – but both theories have yet to be proven.

“I think we should ease off a bit and understand exactly how they (psychedelics) work in order to optimize it,” Corlett said. “They don’t work for everyone.”

In rural Oregon, psilocybin is on the ballot — but remains a mystery Wed, 02 Nov 2022 12:00:11 +0000 Gilliam County Commissioner Pat Shannon voted to put a psilocybin opt-out on the ballot. He’s not convinced that psilocybin therapy can help conditions like depression, anxiety and addiction. Kristian Foden-Vencil/OPB Your browser does not support the audio element. Pat Shannon is a restaurateur and commissioner from Gilliam County in …]]>
depression, anxiety and addiction.” height=”3644″ width=”5209″/>

Gilliam County Commissioner Pat Shannon voted to put a psilocybin opt-out on the ballot. He’s not convinced that psilocybin therapy can help conditions like depression, anxiety and addiction.

Kristian Foden-Vencil/OPB

Pat Shannon is a restaurateur and commissioner from Gilliam County in north-central Oregon.

He and two county council colleagues voted to put a ballot measure removing Gilliam County from Oregon’s new psilocybin therapy program, before voters in November.

He’s also a recovering alcoholic, “I’ve always been a daily drinker,” he said in a recent conversation at the Condon Chamber of Commerce. “Since the day I got out of high school.”

Shannon hasn’t touched a drop in 37 years; today, he still attends meetings and sponsors three recovering alcoholics. So he said he tends to see things through the prism of addiction, and he’s not convinced that using psilocybin to treat depression, anxiety, addiction or other mental health issues would work.

“I just don’t see where you’re going to make a discovery by going on a mushroom trip,” Shannon said.

High Street in Condon, Oregon in October 2022. Most people OPB spoke to in Condon say they don't like what cannabis legalization has done in Oregon, and they aren't convinced that psilocybin will work.

High Street in Condon, Oregon in October 2022. Most people OPB spoke to in Condon say they don’t like what cannabis legalization has done in Oregon, and they aren’t convinced that psilocybin will work.

Kristian Foden-Vencil/OPB

Measures to ban psilocybin are on the November ballot in 104 cities and 27 of Oregon’s 36 counties; which includes the county of Gilliam and the town of Condon. But Shannon said the issue just wasn’t on people’s radars.

“Community members in Gilliam County probably don’t even understand the details of it,” he said.

Shannon said that for many people, psilocybin use is simply lumped in with measure 110.

Oregon voters agreed in 2020 to eliminate criminal consequences for possessing small amounts of illicit drugs, such as heroin and cocaine. Instead of taking someone to jail for possession, police can now only issue an offence, such as a traffic ticket, up to $100. People can avoid this fine if they are willing to contact an addiction service.

The goal is to push people towards recovery, not towards the criminal justice system.

Shannon doesn’t buy it. And he sees a direct line between Measure 110, the effort to decriminalize drugs, and Measure 109, which voters also approved in 2020. It legalized the use of psilocybin in therapeutic settings. Regulators are now drawing up the precise policy guidelines that will govern the program, which will come into effect in January.

Shannon worries that psilocybin is a gateway drug, whether or not it’s addictive.

The new psilocybin therapy program does not allow people to simply buy the drug and take it home, like cannabis. But Shannon believes the program will normalize psilocybin use and abuse.

To be clear, the new program involves people meeting with a facilitator multiple times, discussing their reasons for wanting to take psilocybin, and being closely monitored while using the drug. Such a system is time consuming and will likely cost thousands rather than hundreds of dollars.

Nurse Carol Phillips has helped drug patients on several occasions and she doesn't think psilocybin therapy should be allowed in Gilliam County.

Nurse Carol Phillips has helped drug patients on several occasions and she doesn’t think psilocybin therapy should be allowed in Gilliam County.

Kristian Foden-Vencil/OPB

Still, most people this reporter spoke to in Gilliam County shared Shannon’s views. They say they don’t like what cannabis legalization has done in Oregon, and they’re not convinced psilocybin will work.

They also did not see any advertisements on the subject or speak to any canvassers.

“Stuff like that is really dangerous,” said Carol Phillips, a local nurse. “People are going to abuse it and then they’re going to blame a doctor or someone innocent.”

Retired Debra James saw people take magic mushrooms and didn't like the results.

Retired Debra James saw people take magic mushrooms and didn’t like the results.

Kristian Foden-Vencil/OPB

Disabled retiree Debra James said she has seen people use magic mushrooms.

“The end result is not good,” she said. “They were panicking. Like maybe too much. They weren’t comfortable. They were upset. They were scared.”

James said she doesn’t think a facilitator would be helpful on a bad trip, whether or not they’re trained and licensed.

Such feelings are nothing new to Sam Chapman, the executive director of the Healing Advocacy Fund, a group created to bring psilocybin to Oregon.

“It’s not entirely surprising that some aspects of the state are just saying they’re not ready to move forward with this,” Chapman said. “It’s okay. We are ready to meet anyone and anyone where they are, and we recognize that it takes time.

Sam Chapman, executive director of the Healing Advocacy Fund, said he was not shocked that many Oregonians questioned the idea of ​​psilocybin therapy, even though a majority of voters agreed to allow it. .

Sam Chapman, executive director of the Healing Advocacy Fund, said he was not shocked that many Oregonians questioned the idea of ​​psilocybin therapy, even though a majority of voters agreed to allow it. .

Kristian Foden-Vencil/OPB

Chapman thinks attitudes will change when the program goes live in 137 cities and 10 counties next year. He thinks people will become more tolerant seeing how psilocybin helps.

Chapman also notes that there are volunteers who go door to door in rural areas, trying to educate people about psilocybin therapy. Maybe not so much in Gilliam County, but definitely in places like Jackson County.

That’s because in Jackson County, major cities like Medford and Ashland are pushing ahead with psilocybin as county voters consider a no-vote vote.

Ashland Mayor Julie Akins has a husband who is a veterinarian in Vietnam. He had a stroke, became depressed and lost his sense of balance. She thinks psilocybin might help.

“If you don’t want this therapy, you don’t have to get it,” Akins said. “But making it unavailable to people who need it doesn’t make sense to me.”

Pulling out will just mean sick people will have to travel for treatment, she said.

Ashland Mayor Julie Akins on a Zoom call in October 2022,

Ashland Mayor Julie Akins on a Zoom call in October 2022, “If you don’t want this therapy, you don’t have to get it,” Akins said. “But making it unavailable to people who need it doesn’t make sense to me.”

Kristian Foden-Vencil/OPB

Myles Katz recently purchased the Buckhorn Springs Resort in Jackson County with a view to building a psilocybin service center. He also helped organize the local effort Vote No on 15-203 to raise funds and awareness of the benefits of psilocybin therapy.

Myles Katz's company bought a property in Jackson County to use as a psilocybin service center.

Myles Katz’s company bought a property in Jackson County to use as a psilocybin service center.

Kristian Foden-Vencil/OPB

“When voters were presented with the facts, they were overwhelmingly in favor of what it could bring them,” Katz said. “It’s really the lack of education that would cause them to vote against setting up psilocybin services.”

Ashland and Medford’s differences from Jackson County are mirrored in other places in Oregon. For example, Deschutes County has an opt-out measure on its ballot, while psilocybin therapy will go live in Bend next year.

Back in Gilliam County, pharmacist Anna Charapata counts pills for customers at Murray’s Pharmacy on Condon High Street. She views psilocybin therapy differently than most locals interviewed by the OPB. She thinks psilocybin therapy is a responsible way to learn more about the drug.

“I’ve read about uses in palliative care, so when people die,” Charapata said. “To me, that’s where the strongest evidence of any kind of medical use is: it’s the people facing their mortality.”

Pharmacist Anna Charapata thinks psilocybin therapy is a responsible way to learn more about the drug.

Pharmacist Anna Charapata thinks psilocybin therapy is a responsible way to learn more about the drug.

Kristian Foden-Vencil/OPB

Regardless of what voters decide in this election, two and a half million Oregonians will have local access to psilocybin therapy next year. This covers several rural areas, including Klamath Falls and Grants Pass.

Depression linked to lower likelihood of having children | Latest news for doctors, nurses and pharmacists Sat, 29 Oct 2022 06:37:32 +0000

According to a study, men and women with treated depression appear to be less likely to have children or have fewer children compared to their counterparts without the condition.

Researchers conducted a nationwide cohort study that involved 1,408,951 people born in Finland between 1960 and 1980. They identified diagnoses of depression using health care registry data (this i.e. inpatient episodes 1969-2017 and outpatient specialist visits 1996-2017).

The main study outcomes of having biological children, the number of biological children and the age at first birth were determined using Statistics Finland’s population register and set to either the last year from follow-up in 2017, either in the last year of life or living in Finland.

Depression treated in secondary care was associated with a lower probability of having children in both men (odds ratio [OR]0.66, 95% confidence interval [CI]0.64-0.67) and women (OR, 0.84, 95% CI, 0.82-0.85), as well as with fewer children (men: rate ratio impact [IRR], 0.86, 95% CI, 0.86–0.87; women: IRR, 0.96, 95% CI, 0.96–0.96).

Depression was correlated with a slightly lower age at first birth (men: 33.1 vs 34.0 years, p<0.001; women: 31.3 vs 32.1 years, p<0.001). Severity of depression showed dose-response associations with reduced likelihood of having children and fewer children. Both outcomes were also related to early onset depression and depression in men and women in the middle and high education groups.

No association was observed for low-educated men, while depression was correlated with a higher likelihood of having children and a higher number of children among low-educated women.

UMass Chan study targets maternal health, hypertension and mental health risks with postpartum awareness Thu, 27 Oct 2022 11:07:55 +0000

Researchers from UMass Chan Medical School are collaborating with researchers from Yale University and the University at Buffalo to study increasing levels of awareness and support at home to improve maternal health in the post-natal period. partum among historically underserved and at-risk populations.

The nearly $20 million, five-year funding period supported by the Patient-Centered Outcomes Research Institute begins in early November at UMass Chan.

Tiffany Moore Simas, MD, MPH, MEd

“The study is intended to respond to the public health crisis of increasing maternal mortality in the United States, especially as it disproportionately affects populations marginalized by racism and socioeconomic disadvantage. “said the site’s lead researcher, Tiffany Moore Simas, MD, MPH, MEd, on Donna M. and Robert J. Manning Chair in Obstetrics and Gynecology and President and Professor of Obstetrics and Gynecology. “It does this by targeting the most common causes of preventable maternal mortality and morbidity – cardiovascular conditions, including hypertension and mental health issues – and we are trying to do this in a way that will be sustainable and that may continue beyond the study.

The study involves a “tiered design,” in which each of the three sites will sequentially apply two interventions beyond the routine standard of care, Dr. Moore Simas explained. Sites will add these interventions at staggered times.

Beginning approximately May 2024, eligible postpartum patients seen by physicians at UMass Memorial Health will be contacted by obstetrical extenders (OBs), who at UMass Chan will be nurse practitioners who will telephone patients in their homes. Patients will remotely monitor their blood pressure, which the nurse practitioner will review. OB extenders will also screen for and treat depression and anxiety.

The second scaled-up intervention, called the community health model, will begin locally around February 2026. In addition to remote medical care from OB extenders, patients will be matched with community health workers such as postpartum doulas who will visit patients ; screen them for social determinants of health such as housing, employment and food security; and connect them with resources.

Lara Kovell, MD

“Across the entire study, all caregivers who interact with perinatal individuals will receive training in anti-racism and trauma-informed care. A subset of caregivers will receive additional training on how to deal with mental health and blood pressure control issues, as well as parental intervention to help with parent-child attachment, and how to assess social determinants health and connect with the necessary resources,” says Moore Simas.

The main goals of the project are to improve mean postpartum systolic blood pressure at six weeks and reduce the severity of depression at three months postpartum.

“About 10 to 15 percent of all pregnancies are affected by hypertensive disorders, including gestational hypertension, chronic hypertension, or preeclampsia,” said Lara Kovell, MD, assistant professor of medicine and co-investigator. “A good portion, about 50%, remain hypertensive after childbirth and 10% of those with normal blood pressure during pregnancy develop hypertension in the postpartum period. Hypertension is one of the main reasons for which our patients are admitted to hospital in the postpartum period.

Nancy Byatt, DO

Nancy Byatt, DO, professor of psychiatry, obstetrics and gynecology, and quantitative and population health sciences, who is the site manager for the mental health aspects of the study, said this research s builds on what UMass Chan has developed in partnership with professional organizations to integrate screening, assessment, and treatment for anxiety and depression into the obstetrical workflow.

“We focus on mental health in addition to hypertension because medical conditions don’t happen in a box. They arise in the context of mental health and overall family health, which are often affected by trauma or negative experiences,” Dr. Byatt said. “We will train caregivers to provide mental health care using a relational health and trauma-informed approach. We are also adding testing approaches that take place alongside the medical setting, rather than within a medical setting.

Current articles related to UMass Chan:
Next Generation of VA Researchers to Explore Maternal Health in New Summer Research Training Program
Why pregnant women should get the COVID-19 vaccine – says a maternal care expert

Speak innovatively | MUSK | Charleston, South Carolina Thu, 20 Oct 2022 18:38:14 +0000

Join Jesse Goodwin, Chief Innovation Officer at MUSC, on the “Innovatively Speaking” podcast, where she dives into the origins of the next big things! We will explore the who, why and how of ideas that are changing what is possible at MUSC and, in some cases, across the world! Subscribe through your favorite podcast app and listen to conversations with expert guests whose groundbreaking ideas and technology are reshaping life and healthcare in exceptional ways!

Episode One: Tackling Postpartum Depression and Anxiety with Connie Guille, MD

Our innovation team sits down with Connie Guille, MD, director of the Division of Women’s Reproductive and Behavioral Health (WRBH) at MUSC and associate professor in the departments of Psychiatry and Health and Behavioral Sciences and Obstetrics and gynecology. Dr. Guille discusses his innovative new screening process, “Listening to Women,” which is being adopted in OBGYN care nationwide as well as postpartum depression and anxiety.

Episode 2: Astronauts, Anxiety and Travel to Landmarks with Mark George, MD

Hear from Dr. Mark George, Emeritus Professor of Psychiatry at MUSC and a pioneer in the field of brain stimulation and treatments! Dr. George discusses the treatment of depression, OCD, PTSD and more through the use of magnets (transcranial magnetic stimulation) as well as the possibility of treating NASA astronauts suffering from depression on the way to March !

Episode 3: The Most Common Illness You’ve Never Heard Of with Chip Norris, Ph.D., and Cortney Gensemer, Ph.D.

Joining the show are Dr. Chip Norris and Dr. Cortney Gensemer, both of MUSC’s internationally renowned Norris Laboratory, to discuss some misunderstandings about Ehlers Danlos Syndrome (EDS). EDS is believed to be the most common disease you’ve never heard of, affecting almost 1 in 300 people. Norris and Gensemer show how learning about the condition could help parents deal with the constant pain at which their children may face.

Use of telehealth platform linked to higher rate of remission of suicidal ideation Fri, 14 Oct 2022 18:01:42 +0000

October 14, 2022

2 minute read


Disclosures: Winsberg is employed and owns shares of Brightside Health Inc. Please see the study for relevant financial information from all other authors.

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact

Those who received psychiatric care via a telehealth platform saw a greater level of remission from suicidal ideation after 12 weeks compared to those who did not receive similar care, researchers reported in JMIR Formative Research.

“A recent survey revealed significantly elevated rates of [suicidal ideation] among 18-24 year olds, minority groups, unpaid carers and essential workers,” Mirène Winsbergdoctor, of Brightside Health Inc., a San Francisco company that provides telepsychiatric care, and colleagues wrote. “Taken together, these trends underscore a critical need for better understanding of predictive suicide risks and effective mediation.”

Source: Adobe Stock.

The researchers aimed to examine the impact of telepsychiatric care on changes in suicidal ideation over time and on remission.

Winsberg and colleagues conducted a longitudinal observational study, which used Brightside patient records to include 8,581 US-based adults (8,366 in the treatment group and 215 in the control group) seeking treatment for depression, anxiety, or both, between October 2018 and April 2021.

People in the treatment group had completed at least 12 weeks of treatment and had received a prescription for at least one psychiatric medication during the study period. Individuals in the control group completed baseline enrollment data and completed surveys at baseline and at 12 weeks, but did not receive care. Participants also received decision support at the start of treatment via Brightside’s digital platform.

Participants’ responses to item 9 of the Patient Health Questionnaire-9 were used as an indicator of the severity of suicidal ideation (SI). Follow-ups were performed at week 12 of treatment or any time before week 16.

The results showed that greater feelings of hopelessness, anhedonia and ill-being correlated most significantly (r = 0.24-0.37) with SI at the start of treatment. Sleep problems and fatigue or lack of energy, although significant, had weaker correlations with SI (r = 0.13-0.14). Although not different at baseline, SI expression was evident in 34.4% (74 of 215) of participants in the control group and 12.32% (1,031 of 8,366) of participants in the treatment group at 12 weeks.

The data further revealed that people in the treatment group were 4.3 times more likely (OR, 4.31; 95% CI, 2.88-6.44) to have complete SI remission than those in the a group of witnesses. Women and those with higher education beyond high school were about 1.4 times more likely (OR, 1.38; 95% CI, 1.18-1.62) to remit than their counterparts .

“These findings align with a growing body of literature demonstrating the effectiveness of using a telehealth platform to deliver mental health services,” Winsberg and colleagues wrote.

5 Things to Know About Colorado’s Psychedelic Ballot Initiative Fri, 14 Oct 2022 09:00:00 +0000

Colorado could become the second state after Oregon to allow the use of certain psychedelic substances that are illegal under federal law.

But while voters in Oregon in 2020 endorsed the supervised use of psychedelic mushrooms, the citizens’ initiative on the Colorado ballot in November goes further. Proposition 122 would allow personal use of psilocybin mushrooms and certain herbal psychedelics by adults 21 and older, but prohibit sales except at licensed “healing centers,” where people could ingest them under the supervision of trained facilitators.

Psychedelics, which can alter a person’s perception and cause hallucinations, are Schedule I controlled substances, which is the federal classification given to drugs considered to have a high potential for abuse and serve no purpose. legitimate medical. However, a body of research still in development has found that psychedelic mushrooms may have health benefits, such as treating depression.

In June, 15 cities and other local US jurisdictions decriminalized possession of psilocybin or downgraded the policing, prosecution or arrest of users. Denver’s 2019 voter-approved initiative made adult possession and use of psilocybin mushrooms the city’s lowest law enforcement priority, and it banned spending resources to enforce related sanctions.

Here are five key things to take in about the initiative in Colorado:

1. What does the Colorado initiative do?

Proposition 122 is one of 11 statewide ballot measures Colorado voters will decide in the Nov. 8 general election. The measure would allow adults to grow, possess and use mushrooms containing the chemicals psilocybin and psilocin, and decriminalize three herbal psychedelics: mescaline (although it specifically excludes peyote cactus), ibogaine (from the root bark of the iboga tree), and dimethyltryptamine (a compound in ayahuasca tea). It would also require the state to create regulations for facilities where adults 21 and older can purchase and take supervised psychedelics. The sale of drugs outside of these facilities would remain illegal.

The measure sets a timeline for the regulatory process and facilities to be operational by the end of 2024 for psilocybin, and the state could expand the list of psychedelic substances to include mescaline, ibogaine and dimethyltryptamine in those facilities starting in 2026. If voters approve the initiative, people who use these psychedelics would be protected from professional discipline or loss of public benefits, and criminal records from prior convictions for offenses made legal under the measurement could be sealed.

The measure goes beyond Oregon’s 2020 voter-approved law allowing people to be treated with a variety of psilocybin, called psilocybe cubensis, in supervised facilities. In Oregon, no facilities have yet opened and state health officials are still finalizing regulations.

2. What are the potential health benefits?

The main argument of proponents for passing the measure is that psychedelic mushrooms and plants have potential mental health benefits. Emerging research and clinical trials are investigating the substances’ effectiveness as an alternative treatment for conditions such as depression, anxiety, and post-traumatic stress disorder. Proponents of the measure say the regulations would increase access for people struggling to find effective mental health care. They also say that psychedelic mushrooms are non-addictive and pose no risk to public safety.

3. What are the risks and unknowns?

Opponents warn that the measure is too far ahead of the science and that the research still in development should not be used to legitimize the legalization of psychedelic mushrooms and plants for medical or recreational use. They also point out that much of the research conducted has involved psychedelic mushrooms and that relatively little is known about the effects of mescaline, ibogaine and dimethyltryptamine.

According to officials from the Department of Justice’s National Drug Intelligence Center, ingestion of psilocybin can produce negative physical effects, such as vomiting, weakness, and lack of coordination, as well as negative psychological effects, such as inability to distinguish fantasy from reality. Psilocybin can trigger episodes of psychosis, so people with a personal or family history of psychosis are generally excluded from studies. Psilocybin can also make heart problems worse.

Many people claim that because psilocybin is derived from plants (technically, mushrooms), it is safer than pharmaceutical drugs created in labs. This distinction has no basis. Many plants are poisonous and many pharmaceutical drugs are derived from natural substances.

4. What does science say?

Early studies have shown that psilocybin can help treatment-resistant depression or anxiety and depression in patients with terminal illnesses. Although the results are promising, the researchers caution that larger samples and more research are needed to understand neurobiological factors and the long-term effects of psilocybin. In 2019, the FDA called psilocybin a “breakthrough therapy,” a designation intended to speed the development of promising drugs. No psychedelics have been approved for medical use so far.

Of the drugs being considered in the Colorado initiative, psilocybin is the most studied. Clinical trials have tested psilocybin in combination with therapy. Unlike antidepressants, which must be taken regularly, psilocybin has been shown to have lasting therapeutic effects after just one, two or three doses. It is unclear whether psilocybin has any health benefits outside of psilocybin-assisted therapy protocols used in clinical studies.

Some research findings show that psilocybin-assisted therapy may be helpful in treating substance use disorders, including nicotine and alcohol addiction. Clinical trials for mescaline, ibogaine and dimethyltryptamine are still in the preliminary stages.

5. Will it spawn another industry like marijuana?

Because psilocybin is naturally occurring, people tend to assume that its path to legalization will follow that of cannabis. However, the compounds have key differences in how they affect people. Psilocybin is unlikely to gain approval as easily as marijuana, which is legal for medical purposes in 39 states and the District of Columbia. Nineteen of those states and DC also allow recreational use.

The Colorado measure expressly prohibits the sale of psychedelics outside of licensed establishments. However, the potential for legalization in the state and elsewhere in the United States has spurred the launch of dozens of companies eager to commercialize the sale and treatment of psilocybin. Some hold retreats in Jamaica, Peru, or Mexico, where they perform ceremonies that reflect the traditional use of psilocybin and other natural psychedelics that date back centuries.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism on health issues. Along with policy analysis and polls, KHN is one of the three main operating programs of the KFF (Kaiser Family Foundation). KFF is an endowed non-profit organization providing information on health issues to the nation.


This story may be republished for free (details).